Introduction
============

Alzheimer's disease (AD) is the most common cause of senile dementia characterized by progressive decline in cognition and behaviors. The cause of AD was complex, and genetic factors contributed to its risk. Mutations on three genes of amyloid precursor protein, presenilin 1, and presenilin 2 are associated with rare familial early-onset AD (EOAD). As for the majority of sporadic AD (SAD), apolipoprotein E gene (*APOE*) was the only one confirmed to be related with SAD risks since 1993,[@b1-cia-10-371],[@b2-cia-10-371] and the results were replicated by many candidate genetic studies in different populations and different regions all around the world.[@b3-cia-10-371] Recent genome-wide association studies found that *APOE* is far more significantly related to AD risk than all the other candidate loci.[@b4-cia-10-371],[@b5-cia-10-371]

The *APOE* gene located in 19q13.2, encoding apoE, which consists of 299 amino acids, is a cholesterol carrier involved in lipid transportation and injury repair in the brain. *APOE* has three common isoforms termed *ε2*, *ε3*, and *ε4*, which could be determined by cysteine--arginine substitutions at residues 112 and 158. The frequencies of these three alleles are different among ethnics.[@b6-cia-10-371] Generally, *ε3* is the most common allele, accounting for 60%--90% of the allelic variation. The *ε2* constitutes 0%--20% of allelic variation and *ε4* constitutes 10%--20% (<http://asia.ensembl.org/Homo_sapiens/Variation/Population>). The *ε4* was proved to increase AD risk in a dose-dependent pattern and lower the age at disease onset compared with *ε4* noncarriers.[@b7-cia-10-371] It was also reported as a risk factor for the conversion of mild cognitive impairment to AD.[@b8-cia-10-371] In contrast, *ε2* was reported to have a "protective" effect on AD risk and to slower cognitive function decline than *ε2*-negative status.[@b9-cia-10-371]

The association between *APOE* polymorphisms and AD risk has been investigated in Caucasian, Hispanic, African American, Japanese, and small numbers of Chinese Han populations.[@b10-cia-10-371]--[@b12-cia-10-371] Other studies of candidate genes and AD risk in Chinese Han population used *APOE ε4*--carrying status as a stratification sign but did not focus on *APOE* itself.[@b13-cia-10-371] Here we investigated a large number of 875 SAD and 1,195 controls of Chinese Han to explore the association between *APOE* polymorphisms and AD risk.

Materials and methods
=====================

Subjects
--------

A total of 875 SAD patients and 1,195 unrelated healthy controls were included in this cross-sectional study. All the subjects were from Chinese Han population. SAD patients were recruited from memory disorders clinics in Huashan Hospital between March 2007 and September 2013 with a median age of 72 years (range 48--100 years). Cognitively normal controls with age, sex, and origins similar to SAD patients were recruited from the community epidemiologic investigations (median age of 69 years, range 48--94 years). The enrollment procedure and the inclusion and exclusion criteria for SAD cases and controls were as previously reported.[@b14-cia-10-371] The diagnosis of AD was according to the criteria of Diagnostic and Statistical Manual of Mental Disorders IV revised. Written consents were obtained from subjects or their legally authorized caregivers. This study was approved by the ethics committee of Huashan Hospital.

Genotyping of *APOE*
--------------------

Genomic DNA was extracted from peripheral blood using a Blood Genomic DNA Extraction Kit (TIANGEN, Shanghai, People's Republic of China). The *APOE* genotypes were determined by multiplex amplification refractory mutation system polymerase chain reaction according to the method previously described.[@b15-cia-10-371]

Statistical analysis
--------------------

Hardy--Weinberg equilibrium tests of *APOE* polymorphisms within the groups were performed using *χ*^2^ analysis. The *χ*^2^ test or Student's *t*-test was used to test for the differences between AD and control subjects in the distribution of sex, age at onset (AAO), and mini-mental state examination scores. The *χ*^2^ test was used to compare the genotypes and allele frequencies between AD patients and control subjects. Odds ratio (OR) and the 95% confidence interval (CI) for testing possible associations between AD and control groups were determined by binary logistic regression analyses; AAO and sex were used as covariates. The potential effects of each genotype on AAO in AD patients were calculated by one-way analysis of variance and further analysis by post hoc least significant difference. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc, Chicago, IL, USA). *P*\<0.05 was considered significant.

Results
=======

General information
-------------------

General information of the participants is shown in [Table 1](#t1-cia-10-371){ref-type="table"}. No significant difference was found in age and sex between the two groups, while the mini-mental state examination score was significantly lower in AD. The distributions of the six common genotypes of *APOE* were under Hardy--Weinberg equilibrium in SAD patients and control subjects, respectively ([Table S1](#SD1-cia-10-371){ref-type="supplementary-material"}).

*ε2* allele decreased AD risk and *ε4* allele increased AD risk
---------------------------------------------------------------

In all the subjects, the distribution of allele frequencies and genotypes of *APOE* was of significant difference between AD and control groups with more *ε2*, *ε3* allele and less *ε4* allele in controls ([Table 2](#t2-cia-10-371){ref-type="table"}). There were also more *ε2*-carrying subjects (*ε2ε2*, *ε2ε3*, and *ε2ε4*) and less *ε4*-carrying subjects (*ε2ε4*, *ε3ε4*, *ε4ε4*) in the control group than in the AD group. When the subjects were further stratified by sex and AAO (AD with AAO ≤65 was defined as EOAD; AAO \>65 as late-onset AD \[LOAD\]), the differences remained significant ([Table 2](#t2-cia-10-371){ref-type="table"}).

The impact of *APOE* genotype and allele frequencies on SAD risks was analyzed by binary logistic regression. As shown in [Table 3](#t3-cia-10-371){ref-type="table"}, in all the subjects, *ε2ε3* genotype decreased AD risk (*P*=8×10^−3^, OR 0.64, 95% CI 0.46--0.89) while *ε2ε2* and *ε2ε4* genotypes did not statistically relate to AD risk. On the contrary, *ε3ε4 and ε4ε4* genotype increased AD risk with dosage effect of *ε4*: the OR of *ε3ε4* was 1.90 (*P*=1.18×10^−9^, 95% CI 1.54--2.33) while the OR of *ε4ε4* rose to 15.64 (*P*=8.59×10^−15^, 95% CI 7.92--32.05). When the subjects were further divided by sex and AAO, the *ε4* dosage effect remained constant, but the protective effect of *ε2ε3* was significant only in the female subgroup and LOAD subgroup. As for the *ε2*- and *ε4*-carrying status, *ε2* allele lowered the risk of developing AD while *ε4* increased this risk, which existed in all subgroups after the subjects were stratified by sex and AAO, with the highest OR of 2.79 in female *ε4*-positive subjects ([Table 3](#t3-cia-10-371){ref-type="table"}).

*APOE ε4ε4* may be associated with an earlier AAO in LOAD patients
------------------------------------------------------------------

In AD patients, only in LOAD was the AAO found to be significantly lower in *ε4* allele-positive subjects than *ε4* allele-negative ones (73.9±5.12 vs 74.9±5.18, *P*=2.2×10^−2^) ([Table 4](#t4-cia-10-371){ref-type="table"}). Nevertheless, there was no difference in AAO between the *ε2*-positive AD and *ε2*-negative ones. We further investigated the AAO according to the dosage of *ε2* and *ε4.* The AAO was 2 years lower in patients of *ε4ε4* genotype than *ε4* carriers (*ε2ε4 and ε3ε4*) or *ε4*-negative ones. But no dosage effect of *ε4* on AAO was found.

We further investigated the effect of *APOE ε2* and *ε4* haplotype on AD risk in different AAO and found *ε2*'s protective role against AD in the patients with AAO of 61--65 and above 76 ([Table 5](#t5-cia-10-371){ref-type="table"}). The *ε4* haplotype increased AD risk in patients with AAO below 55 and 61--75 with the highest OR of 3.842 in 66--70 groups. The risk decreased when AAO was above 76, though there was no significant difference.

Discussion
==========

In 1993, *APOE ε4* was first reported to increase SAD risks and advance AAO of AD in a gene dosage way.[@b1-cia-10-371],[@b2-cia-10-371],[@b16-cia-10-371] Except for several investigations,[@b17-cia-10-371] most studies confirmed the results.[@b18-cia-10-371]--[@b23-cia-10-371] The dose effect of *APOE ε4* on AD risk was reported to be ascribed to increased Aβ, Aβ oligomers, and plaque deposition and reduced metabolism in certain parts of the brain.[@b24-cia-10-371]

The allele frequencies and genotypes vary among different ethnic groups.[@b25-cia-10-371] In our study, the *APOE* allele frequencies (AD: *ε2* 4.8%, *ε3* 68.1%, and *ε4* 27.1%; control *ε2* 8.5%, *ε3* 78.1%, and *ε4* 13.5%) were similar to the *APOE* survey in Shanghai consisting of 65 AD patients and 363 cognitively normal controls (AD: *ε2* 4.6%, *ε3* 70%, and *ε4* 25.4%; control: *ε2* 8.6%, *ε3* 80.4%, and *ε4* 11%).[@b6-cia-10-371] We also found that the *APOE ε4* was the independent risk factor of AD and increased the AD risk in a gene dosage way. This is quite consistent with the investigations in other populations.[@b7-cia-10-371],[@b26-cia-10-371],[@b27-cia-10-371] However, the ORs in *ε3ε4* genotype toward AD risks were relatively smaller in all the subjects and subgroups of LOAD, EOAD, male, and female (1.579--2.159) groups, compared with those reported in other studies[@b7-cia-10-371],[@b21-cia-10-371],[@b25-cia-10-371],[@b28-cia-10-371] (usually \>2). The ORs in *ε4ε4* genotype ranged from 11.061 to 20.581, much greater than those of *ε3ε4* and in accordance with the results in other studies. The genotype of *ε2ε4* showed a risk factor of AD in some studies,[@b7-cia-10-371] but did not show any protective or risk effect on AD pathogenesis in our study, which might be due to the small frequency of *ε2ε4* genotypes or the co-existence of a "protective" and harmful effect in *ε2* allele and *ε4* allele, respectively.

In the present investigation, the *APOE ε2* decreased the AD risks, and *ε2ε3* lowered the AD risk in total population, female, and LOAD subgroups. This effect is similar to those observed in other populations.[@b27-cia-10-371],[@b29-cia-10-371] But the "protective" effect did not always show due to the lower frequency of *ε2* allele.[@b7-cia-10-371],[@b30-cia-10-371] In one study of north Chinese population, the *ε2* was indicated as a protective factor in male population, which was contrary to our result. This might be contributed to their small subject number and imbalanced sex distribution between AD and control groups.[@b12-cia-10-371]

Researches indicated that the *ε4* allele took part in the pathogenesis of EOAD as well,[@b29-cia-10-371],[@b31-cia-10-371] and it was well replicated in our study. But a previous report in Chinese population did not find any association, which could be due to the small number of subjects.[@b12-cia-10-371] Some investigations indicated that *ε4* increased AD risk in women more than men,[@b32-cia-10-371],[@b33-cia-10-371] but others did not find the pattern.[@b21-cia-10-371],[@b29-cia-10-371] In a prospective study in Latin Americans, *APOE* ε*4* allele risk was significant only in women,[@b32-cia-10-371] but had a stronger effect in men from Sweden and Finland.[@b27-cia-10-371],[@b34-cia-10-371] In our population, *APOE ε4* increased AD risk in both sexes with a higher OR in the female group. The different results might be caused by ethnic origins.

*APOE ε2* allele was reported not to affect AAO in AD patients in most studies.[@b31-cia-10-371] The differences of AAO between *ε2ε2* group and one or no *ε2* group did not reach significant, though the AAO of *ε2ε2* was 4 years later in number than that of one *ε2* group. This might be attributed to the very low frequencies of *ε2ε2* genotypes in AD. *APOE ε4* allele was reported to lower the AAO of LOAD in a gene dosage way. The AAO of AD patients with *APOE ε4ε4* genotype was 5--16 years lower than those with *ε4*-negative ones.[@b16-cia-10-371] In our subjects, the AAO had a decrease of 2 years in patients of *ε4ε4* genotype in contrast to *ε4* carriers (*ε2ε4* and *ε3ε4*) or *ε4*-negative ones, but not in a gene dosage way. Though we found some significant differences in AAO in the current study, we still could not deduce the effect of *APOE* genotype on the AAO with respect to the cross-sectional study. So further prospective studies should be implemented in Chinese Han population.

Whether *APOE ε2* would reduce AD risk in a certain AAO range was controversial.[@b27-cia-10-371],[@b35-cia-10-371] We found *ε2*'s protective role in the AAO of 61--65 and above 76. As for *ε4* haplotype, its AD risk decreased in people aged 70 years and above,[@b36-cia-10-371] which was quite similar to our results. There might be other genetic risk factors or environmental effects contributing to the AD onset in very old people.

This study had a few limitations. First, factors like diabetes, history of depression, stroke, and heart attack may also contribute to AD pathogenesis, but due to the incomplete information, we did not put those covariants into the binary logistic regression. Second, the subjects were recruited from memory disorders clinics but not the general population, which might exaggerate the impact of *APOE ε4* on AD risks. In the population-based studies, the positive predictive value was lower, and hence *APOE ε4* is not recommended for a screen test for AD.[@b22-cia-10-371],[@b34-cia-10-371]

In conclusion, the *APOE ε4* allele is a strong risk factor in AD in the Chinese Han population and it affects AD risk in a gene dosage effect, similar to those in other populations. The risk of *APOE ε3ε4* toward AD was relatively smaller and the *APOE ε4ε4* genotype lowered the AAO of AD in the LOAD group, which might be the specific characteristics of *APOE* polymorphisms in the Chinese Han population. The role of *APOE* protein in AD pathogenesis and other loci that will help to increase the AD-predictive value combined with *APOE ε4* should be studied in the future.

Supplementary material
======================

###### 

Hardy--Weinberg equilibrium of *APOE* in AD patients and controls

  *APOE*       AD (actual)     AD (expected)   Controls (actual)   Controls (expected)
  ------------ --------------- --------------- ------------------- ---------------------
  Number       875 (%)                         1,195 (%)           
  *ε2ε2*       4 (0.5)         2 (0.2)         7 (0.6) 1.0         9 (0.8)
  *ε2ε3*       54 (6.2)        57 (6.5)        147 (12.3)          158 (13.2)
  *ε2ε4*       22 (2.5)        22 (2.5)        41 (3.4)            27 (2.3)
  *ε3ε3*       424 (48.5)      406 (46.5)      728 (60.9)          728 (60.9)
  *ε3ε4*       289 (33.0)      322 (36.9)      263 (22.0)          251 (21.0)
  *ε4ε4*       82 (9.4)        64 (7.3)        9 (0.8)             22 (1.8)
  *ε2*         84 (4.8)                        202 (8.5)           
  *ε3*         1,191 (68.1)                    1,866 (78.1)        
  *ε4*         475 (27.1)                      322 (13.5)          
  *ε2* (*P*)   5.137 (0.399)                   9.261 (0.099)       

**Abbreviations:** AD, Alzheimer's disease; *APOE*, apolipoprotein E gene.
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###### 

Characteristics of subjects in AD and control groups

                                                                             AD                   Control               *P*
  -------------------------------------------------------------------------- -------------------- --------------------- --------------------------------------------------
  Number                                                                     875                  1,195                 
  Age[a](#tfn2-cia-10-371){ref-type="table-fn"} (mean ± SD) (range), years   67.7±9.67 (45--97)   68.5±10.13 (48--94)   0.106
  Male/female                                                                397/478              493/702               0.062
  MMSE (mean ± SD)                                                           14.3±6.35            28.6±1.85             0.000[\*](#tfn1-cia-10-371){ref-type="table-fn"}

**Notes:**

*P*\<0.01.

Age at onset for AD; age at entrance for control.

**Abbreviations:** AD, Alzheimer's disease; MMSE, mini-mental state examination; SD, standard deviation.

###### 

Distribution of allele frequencies and genotypes of *APOE* in AD and controls

                 *APOE*   Numbers                                                           Genotypes (%)   Allele frequencies (%)                                                                                                                                                                                                                       
  -------------- -------- ----------------------------------------------------------------- --------------- ----------------------------------------------------------------- ------ --------------------------------------------------------------- ---------------------------------------------------------------- ------ ------ ------ ------ ------ ------
  Total          AD (%)   875                                                               0.5             6.2                                                               2.5    48.5                                                            33.0                                                             9.4    4.8    68.1   27.1   9.1    44.9
  Control (%)    1,195    0.6                                                               12.3            3.4                                                               60.9   22.0                                                            0.8                                                              8.5    78.1   13.5   16.3   26.2   
  *χ*^2^ (*P*)            143.5 (3.15×10^−29^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                   131.3 (3.08×10^−29^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}          22.6 (2.02×10^−6^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}   78.8 (6.94×10^−19^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                                      
  Male           AD       397                                                               0.3             7.1                                                               2.3    51.6                                                            31.2                                                             7.6    4.9    70.8   24.3   9.6    41.1
  Control        493      0.6                                                               11.6            4.5                                                               59.8   22.7                                                            0.8                                                              8.6    77.0   14.4   16.6   28.0   
  *χ*^2^ (*P*)            43.2 (3.39×10^−8^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                     33.9 (4.37×10^−8^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}            9.4 (0.002)[\*](#tfn4-cia-10-371){ref-type="table-fn"}          16.8 (4.21×10^−5^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                                       
  Female         AD       478                                                               0.6             5.4                                                               2.7    45.8                                                            34.5                                                             10.7   4.7    65.8   29.5   8.8    48.1
  Control        702      0.6                                                               12.8            2.7                                                               61.7   21.5                                                            0.7                                                              8.3    78.8   12.8   16.1   24.9   
  *χ*^2^ (*P*)            107.5 (1.35×10^−21^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                   104.9 (1.82×10^−23^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}          13.3 (2.63×10^−4^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}   67.8 (1.78×10^−16^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                                      
  EOAD           AD       354                                                               0               6.5                                                               2.8    49.7                                                            32.5                                                             8.5    4.7    69.2   26.1   9.3    43.8
  Control        483      0.8                                                               11.4            4.6                                                               60.9   21.7                                                            0.6                                                              8.8    77.4   13.8   16.8   26.9   
  *χ*^2^ (*P*)            55.2 (1.17×10^−10^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                    46.5 (7.88×10^−11^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}           9.6 (0.002)[\*](#tfn4-cia-10-371){ref-type="table-fn"}          25.9 (3.61×10^−7^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                                       
  LOAD           AD       521                                                               0.8             6.0                                                               2.3    47.6                                                            33.4                                                             10.0   4.9    67.3   27.8   9.0    45.7
  Control        712      0.4                                                               12.9            2.7                                                               61.0   22.2                                                            0.8                                                              8.2    78.5   13.3   16.0   25.7   
  *χ*^2^ (*P*)            92.6 (1.92×10^−18^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                    85.7 (2.45×10^−19^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}           13.0 (3.20×10^−4^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}   53.4 (2.71×10^−13^)[\*](#tfn4-cia-10-371){ref-type="table-fn"}                                      

**Note:**

*P*\<0.01.

**Abbreviations:** AD, Alzheimer's disease; *APOE*, apolipoprotein E gene; EOAD, early-onset AD; LOAD, late-onset AD.

###### 

Logistic regression of *APOE* genotypes and allele frequencies in Alzheimer's disease patients and controls

  Total     *ε2ε2*        *ε2ε3*                                                  *ε2ε4*       *ε3ε3*   *ε3ε4*                                                   *ε4ε4*                                                    *ε2* (+)                                                 *ε4* (+)
  --------- ------------- ------------------------------------------------------- ------------ -------- -------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------
   *P*      0.994         8×10^−3^[\*](#tfn6-cia-10-371){ref-type="table-fn"}     0.682        1.ref    1.18×10^−9^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   8.59×10^−15^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   2.88×10^−6^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   1.57×10^−18^[\*](#tfn6-cia-10-371){ref-type="table-fn"}
   OR       1.01          0.64                                                    0.90                  1.90                                                     15.93                                                     0.52                                                     2.30
   95% CI   0.29--3.46    0.46--0.89                                              0.53--1.53            1.54--2.33                                               7.92--32.05                                               0.39--0.68                                               1.91--2.77
  Male                                                                                                                                                                                                                                                                              
   *P*      0.50          0.22                                                    0.16         1.ref    4×10^−3^[\*](#tfn6-cia-10-371){ref-type="table-fn"}      8.87×10^−6^[\*](#tfn6-cia-10-371){ref-type="table-fn"}    6×10^−3^[\*](#tfn6-cia-10-371){ref-type="table-fn"}      7.22×10^−5^[\*](#tfn6-cia-10-371){ref-type="table-fn"}
   OR       0.46          0.735                                                   0.561                 1.58                                                     11.06                                                     0.54                                                     1.77
   95% CI   0.05--4.42    0.45--1.20                                              0.25--1.25            1.16--2.16                                               3.83--31.94                                               0.36--0.81                                               1.34--2.34
  Female                                                                                                                                                                                                                                                                            
   *P*      0.61          1.8×10^−2^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   0.41         1.ref    3.79×10^−8^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   2.02×10^−10^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   3.19×10^−4^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   4.61×10^−16^[\*](#tfn6-cia-10-371){ref-type="table-fn"}
   OR       1.48          0.57                                                    1.36                  2.16                                                     20.58                                                     0.50                                                     2.79
   95% CI   0.33--6.66    0.36--0.91                                              0.66--2.80            1.64--2.84                                               8.10--52.27                                               0.35--0.73                                               2.18--3.58
  EOAD                                                                                                                                                                                                                                                                              
   *P*      1.00          0.25                                                    0.45         1.ref    4.17×10^−4^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   1.91×10^−6^[\*](#tfn6-cia-10-371){ref-type="table-fn"}    3×10^−3^[\*](#tfn6-cia-10-371){ref-type="table-fn"}      6.73×10^−7^[\*](#tfn6-cia-10-371){ref-type="table-fn"}
   OR       0.00          0.74                                                    0.74                  1.80                                                     18.83                                                     0.52                                                     2.10
   95% CI   0             0.44--1.24                                              0.34--1.61            1.30--2.50                                               5.63--63.03                                               0.34--0.80                                               1.57--2.81
  LOAD                                                                                                                                                                                                                                                                              
   *P*      0.28          2.3×10^−2^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   0.82         1.ref    1.18×10^−6^[\*](#tfn6-cia-10-371){ref-type="table-fn"}   1.25×10^−9^[\*](#tfn6-cia-10-371){ref-type="table-fn"}    1.0×10^−3^[\*](#tfn6-cia-10-371){ref-type="table-fn"}    9.73×10^−13^[\*](#tfn6-cia-10-371){ref-type="table-fn"}
   OR       2.30          0.60                                                    1.09                  1.94                                                     14.41                                                     0.53                                                     2.41
   95% CI   0.51--10.41   0.39--0.93                                              0.52--2.28            1.48--2.53                                               6.09--34.08                                               0.37--0.76                                               1.89--3.07

**Note:**

*P*\<0.01.

**Abbreviations:** *APOE*, apolipoprotein E gene; CI, confidence interval; EOAD, early-onset Alzheimer's disease; LOAD, late-onset Alzheimer's disease; OR, odds ratio.

###### 

The *APOE ε2* and *ε4* allele dosage effect on age at onset in AD patients

                  *ε2* (+)          *ε2* (−)                                                      No *ε2*            One *ε2*           Two *ε2*                                              
  --------------- ----------- ----- ----------------------------------------------------- ------- ------------ ----- ------------ ----- ----------------------------------------------------- ----
  Total AAO, n    67.7±9.60   80    67.7±9.69                                             795     67.7±9.69    795   67.5±9.75    76    72.0±4.97                                             4
  EOAD AAO, n     57.9±4.30   33    57.7±5.09                                             321     57.7±5.01    321   57.9±4.30    33    0                                                     0
  LOAD AAO, n     74.6±5.30   47    74.4±5.17                                             474     74.4±5.17    474   74.9±5.32    43    72.0±4.97                                             4
  Male AAO, n     67.0±9.24   38    67.6±9.77                                             359     67.6±9.77    359   66.7±9.18    37    78.0                                                  1
  Female AAO, n   68.4±9.98   42    67.8±9.63                                             436     67.8±9.62    436   68.3±10.32   39    70.0±9.64                                             3
                  *ε4* (+)          *ε4* (−)                                                      No *ε4*            One *ε4*           Two *ε4*                                              
  Total AAO, n    67.9±9.80   706   68.2±10.01                                            1,364   67.8±9.95    482   67.6±9.69    311   67.4±7.88                                             82
  EOAD AAO, n     58.0±5.13   155   57.6±4.93                                             199     57.6±4.93    199   57.6±5.20    125   59.2±4.72                                             30
  LOAD AAO, n     73.9±5.12   238   74.9±5.18[a](#tfn8-cia-10-371){ref-type="table-fn"}   283     74.9±5.18    283   74.4±5.10    186   72.2±4.86[b](#tfn9-cia-10-371){ref-type="table-fn"}   52
  Male AAO, n     67.8±9.58   163   67.3±9.82                                             234     67.3±9.81    234   67.6±9.85    133   68.6±8.38                                             30
  Female AAO, n   67.5±9.17   230   68.2±10.08                                            248     68.2±10.08   248   67.7±9.59    178   66.7±7.57                                             52

**Notes:**

Difference between AAO in LOAD in *ε4* (+) and *ε4* (−) status was significant (*P*=0.022).

Difference between AAO in LOAD in carriers of one and two *APOEε4* alleles was significant (*P*=0.006).

**Abbreviations:** AD, Alzheimer's disease; AAO, age at onset; *APOE*, apolipoprotein E gene; EOAD, early-onset AD; LOAD, late-onset AD.

###### 

Effect of *APOE ε2* and *ε4* haplotype on AD risk stratified by age

             AAO         AD (%)      Control (%)                                                 *P*-value                                           OR (95% CI)
  ---------- ----------- ----------- ----------------------------------------------------------- --------------------------------------------------- ----------------------
  ε*2* (+)   ≤55         9 (8.0)     26 (15.8)                                                   0.088                                               0.492 (0.218--1.110)
  56--60     15 (11.7)   20 (15.2)   0.572                                                       0.810 (0.391--1.680)                                
  61--65     9 (7.9)     35 (18.8)   0.016[\*](#tfn11-cia-10-371){ref-type="table-fn"}           0.382 (0.175--0.833)                                
  66--70     13 (10.0)   20 (12.9)   0.422                                                       0.737 (0.349--1.554)                                
  71--75     16 (8.7)    6 (14.6)    0.062                                                       0.552 (0.296--1.030)                                
  76--80     11 (7.9)    31 (18.6)   0.009[\*\*](#tfn12-cia-10-371){ref-type="table-fn"}         0.376 (0.181--0.781)                                
  \>80       7 (10.3)    27 (18.9)   0.027[\*](#tfn11-cia-10-371){ref-type="table-fn"}           0.888 (0.800--0.986)                                
  ε*4* (+)   ≤55         51 (45.5)   49 (29.7)                                                   0.010[\*](#tfn11-cia-10-371){ref-type="table-fn"}   1.954 (1.173--3.256)
  56--60     49 (38.3)   35 (26.5)   0.051                                                       1.700 (0.998--2.896)                                
  61--65     55 (48.2)   46 (24.7)   5.13×10^−5^[\*\*](#tfn12-cia-10-371){ref-type="table-fn"}   2.817 (1.706--4.650)                                
  66--70     73 (56.2)   39 (25.2)   1.59×10^−7^[\*\*](#tfn12-cia-10-371){ref-type="table-fn"}   3.842 (2.323--6.355)                                
  71--75     84 (45.7)   54 (21.9)   2.99×10^−7^[\*\*](#tfn12-cia-10-371){ref-type="table-fn"}   3.011 (1.975--4.590)                                
  76--80     55 (39.6)   53 (31.7)   0.149                                                       1.417 (0.883--2.276)                                
  \>80       26 (38.2)   37 (25.9)   0.073                                                       1.772 (0.948--3.314)                                

**Notes:**

*P*\<0.05

*P*\<0.01.

**Abbreviations:** AAO, age at onset; AD, Alzheimer's disease; *APOE*, apolipoprotein E gene; CI, confidence interval; OR, odds ratio.
